浙江亨通控股股份有限公司 董事会议事规则 第一条 宗旨 为了进一步规范浙江亨通控股股份有限公司(以下简称"公司"或"本公 司")董事会的议事方式和决策程序，促使公司董事和董事会有效地履行其职责， 提高公司董事会规范运作和科学决策水平，根据《公司法》《证券法》《上市公 司治理准则》《上海证券交易所股票上市规则》等有关规定和《浙江亨通控股股 份有限公司章程》(以下简称"《公司章程》")，制定本规则。 第二条 董事会日常事务处理部门 董事会下设董事会办公室，处理董事会日常事务。董事会秘书负责保管董事 会印章。 第三条 定期会议 董事会会议分为定期会议和临时会议。 董事会每年应当至少召开两次定期会议。 第四条 定期会议的提案 在发出召开董事会定期会议的通知前，董事会办公室应当充分征求各董事的 意见，初步形成会议提案后交董事长拟定。 董事长在拟定提案前，应当视需要征求总裁和其他高级管理人员的意见。 第五条 临时会议 有下列情形之一的，董事会应当召开临时会议： （一）代表十分之一以上表决权的股东提议时； 第六条 临时会议的提议程序 按照前条规定提议召开董事会临时会议的，应当通过董事会办公室或者直接 向董事长提交经提议人签 ...

浙江亨通控股股份有限公司 关联交易决策权限与程序规则 第一章 总则 第一条 为规范浙江亨通控股股份有限公司（以下简称"公司"）关联交易行 为，保护公司和投资者的合法权益，根据《中华人民共和国公司法》 （以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上海证 券交易所股票上市规则》（以下简称"《股票上市规则》"）、《上海证券交易所 上市公司自律监管指引第 5 号——交易与关联交易》等有关法律、法规、规范性文 件以及《浙江亨通控股股份有限公司章程》（以下简称"《公司章程》"）的有关 规定，制定本规则。 第二条 公司进行关联交易应遵循以下基本原则： （一）诚实信用原则； （二）平等、自愿、等价、有偿的原则； （三）公正、公平、公开的原则。关联交易的价格或收费原则上应不偏离市场 独立第三方的标准，对于难以比较市场价格或订价受到限制的关联交易，应通过合 同明确有关成本和利润的标准。公司应对关联交易的定价依据予以充分披露； （四）关联股东及董事回避原则； （五）公司董事会应当根据客观标准判断关联交易是否对公司有利，必要时应 当聘请证券律师、专业评估师或独立财务顾问发表意见。 第三条 公司 ...

浙江亨通控股股份有限公司 募集资金使用管理办法 第一章 总则 第一条 为规范浙江亨通控股股份有限公司（以下简称"公司"）募集资金 的管理和使用，保护投资者利益，根据《中华人民共和国公司法》《中华人民共 和国证券法》《上市公司证券发行管理办法》《上海证券交易所股票上市规则》 （以下简称"《股票上市规则》"）、《上市公司募集资金监管规则》《上海证 券交易所上市公司自律监管指引第 1 号——规范运作》等法律法规、规范性文件 以及《浙江亨通控股股份有限公司章程》（以下简称"《公司章程》"）的规定， 并结合公司实际情况，特制定本办法。 第二条 本办法所称募集资金是指公司通过发行股票或者其他具有股权性质 的证券，向投资者募集并用于特定用途的资金监管，但不包括公司实施股权激励 计划募集的资金监管。 公司董事会应当对募集资金投资项目（以下简称"募投项目"）的可行性进 行充分论证，确信投资项目具有较好的市场前景和盈利能力，有效防范投资风险， 提高募集资金使用效益。 第三条 公司对募集资金的管理遵循专户存放、专款专用、严格管理、如实 披露的原则。公司董事会负责建立并完善募集资金存储、使用和管理的内部控制 制度，对募集资金存储、使 ...

Core Viewpoint - Zhejiang Hengtong Holding Co., Ltd. reported a significant increase in revenue and net profit for the first half of 2025, driven primarily by the growth in copper foil sales and steam business profits [2][12][13]. Company Overview and Key Financial Indicators - The company achieved an operating income of 818.21 million yuan, a year-on-year increase of 45.80% [2][12]. - The total profit reached 140.72 million yuan, up 16.68% from the previous year [2][12]. - The net profit attributable to shareholders was 126.95 million yuan, reflecting an 8.91% increase [2][12]. - The company's total assets grew by 7.07% to 4.81 billion yuan, while net assets increased by 3.96% to 3.55 billion yuan [2][12]. Industry and Main Business Situation - The company's revenue primarily comes from the production and sales of electrolytic copper foil, veterinary drugs, and feed additives, as well as combined heat and power supply [12][13]. - The electrolytic copper foil market is expected to grow due to increasing demand from the PCB industry and the rise of AI applications, which require high-performance materials [12][13]. - The global PCB market is projected to grow at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2029, reaching approximately 94.66 billion USD by 2029 [12][13]. - The lithium battery copper foil market is also expanding, driven by the growth of the new energy vehicle sector and energy storage systems [12][13]. Business Performance and Development - The company’s subsidiary, Hengtong Copper Foil, has successfully developed high-value-added products such as reverse copper foil (RTF) and low-profile copper foil (LP), which are now in mass production [12][13]. - The company is actively expanding its market presence and enhancing its product offerings in high-end copper foil products to meet the increasing demands of the electronics industry [12][13]. - The company is investing in a small variety amino acid production base, which will add 11,880 tons/year of production capacity, enhancing its competitive position in the amino acid market [12][15]. Research and Development - Hengtong Copper Foil has established a robust R&D framework, collaborating with renowned universities to innovate and improve product quality [12][19]. - The company has applied for 70 patents and received 25 authorizations, indicating a strong commitment to technological advancement and intellectual property protection [12][19]. Market Trends - The demand for feed additives, particularly amino acids, is expected to grow due to the increasing focus on animal nutrition and the reduction of soybean meal in feed formulations [12][7]. - The veterinary drug market is also expanding, with the company focusing on international markets, particularly in South America and Asia [12][16].

Core Viewpoint - Zhejiang Hengtong Holdings Co., Ltd. reported significant growth in revenue and total assets for the first half of 2025, indicating a strong operational performance despite a decline in net profit attributable to shareholders [1][2]. Financial Performance - Total assets increased to CNY 4,813.56 million, up 7.07% from the previous year [1]. - Operating revenue reached CNY 818.21 million, representing a 45.80% increase compared to the same period last year [1]. - Total profit amounted to CNY 140.72 million, a 16.68% rise year-on-year [1]. - Net profit attributable to shareholders decreased by 29.36% to CNY 78.33 million, excluding non-recurring gains and losses [1]. Cash Flow and Shareholder Information - The net cash flow from operating activities was negative at CNY -62.05 million, compared to CNY -48.74 million in the previous year [1]. - The total number of shareholders as of the reporting period was 34,237 [1]. Major Shareholders - Hengtong Group Co., Ltd. holds 16.95% of the shares, amounting to 504,153,332 shares, and is the controlling shareholder [2]. - Other significant shareholders include Suzhou Hengtong Yongxu Venture Capital with 10.83% and Zhangjiagang Puxin Enterprise Management Consulting with 5.24% [2]. Important Developments - The company is set to enhance its production capacity with the completion of a small amino acid production base project, which will add 11,880 tons/year of production capacity, including L-Tryptophan and L-Arginine [5].

Core Viewpoint - Hengtong Holdings reported significant growth in revenue and net profit for the first half of 2025, driven primarily by its copper foil business, which is positioned as a key growth engine for the company [1][2]. Financial Performance - The company achieved a revenue of 818 million yuan, representing a year-on-year increase of 45.80% - Net profit attributable to shareholders was 127 million yuan, up 8.91% year-on-year [1]. Business Segments - The copper foil business contributed 553 million yuan in revenue, accounting for 67.59% of total revenue, with sales volume increasing by 131.33% [1]. - The company has a production capacity of 10,000 tons/year for electronic circuit copper foil and 5,000 tons/year for lithium battery copper foil, with ongoing construction to expand capacity [3]. Market Demand and Trends - The demand for electronic circuit copper foil is closely linked to the rapid development of AI computing power, 5G communication, and new energy vehicles, with a projected compound annual growth rate of 5.2% for global PCB output from 2024 to 2029 [1][2]. - The lithium battery copper foil market is driven by the needs of new energy vehicles and energy storage systems, with increasing demands for higher energy density and longer battery life [1]. Strategic Direction - Hengtong Holdings is focusing on high-end copper foil products, avoiding price wars, and emphasizing R&D and industrial application to capture domestic substitution opportunities [2]. - The company has developed high-value-added products such as RTF, LP, and HTE copper foils, which have already entered mass production [2]. Production and Supply Chain - The company’s production base in Deyang, Sichuan, benefits from local sulfuric acid resources and copper material storage advantages, which help reduce production and transportation costs [3]. - Hengtong Holdings is strengthening partnerships with leading PCB manufacturers, with products being increasingly adopted by major clients [2][3]. Other Business Developments - In addition to copper foil, the company is advancing in the biosynthesis sector, with a project in Inner Mongolia expected to add 11,880 tons/year of amino acid production capacity [3]. - The export performance of products like Monensin is strong, with a 23.50% year-on-year increase in sales [3].

智通财经APP讯，亨通股份(600226.SH)披露2025年半年度报告，报告期公司实现营收8.18亿元，同比增 长45.80%;归母净利润1.27亿元，同比增长8.91%;扣非净利润7833万元，同比下降29.36%;基本每股收益 0.04元。 ...

Group 1 - The company, Hengtong Optic-electric Co., Ltd., announced that it will hold its second extraordinary general meeting of shareholders for 2025 on September 16, 2025 [1] - The agenda for the meeting includes the review of multiple proposals, including amendments to certain governance systems [1]

Core Insights - Hengtong Co., Ltd. reported a revenue of 818 million yuan for the first half of 2025, a year-on-year increase of 45.8%, and a net profit attributable to shareholders of 127 million yuan, up 8.91% year-on-year [1] Group 1: Business Performance - The company's revenue primarily comes from the production and sales of electrolytic copper foil, biological veterinary drugs, feed additives, and related businesses [1] - Copper foil sales increased by 131.33% year-on-year, contributing 5.53 billion yuan to the total revenue, accounting for 67.59% of the company's total revenue [1] Group 2: Product Development - Hengtong's subsidiary has developed high-value-added products such as reverse copper foil (RTF), low-profile copper foil (LP), and high-temperature extended copper foil (HTE), which have entered mass production [1] - In the lithium battery copper foil segment, the company is exploring technologies like porous copper foil and atomized copper foil, with a production capability ranging from 4.5μm to 8μm, and has mastered the production technology for 3.5μm copper foil [2] Group 3: Market Expansion - The company is expanding its overseas market presence, actively pursuing customer certifications and supplying products to clients in Taiwan, India, and Malaysia [4] - Hengtong is also focusing on the South American, Asian, African, and Middle Eastern markets for its veterinary drugs and feed additives, developing cost-effective product combinations tailored to regional market demands [4] Group 4: New Projects - A new amino acid production base is being established in Hohhot, Inner Mongolia, which will add a production capacity of 11,880 tons per year, including L-tryptophan, L-arginine, and L-isoleucine [3]

Group 1 - Hengtong Optic-electric Co., Ltd. held its 22nd meeting of the 9th Board of Directors on August 22, 2025, to review the "2025 Semi-Annual Report" and other documents [1] - For the fiscal year 2024, Hengtong's revenue composition is 97.37% from industrial manufacturing and 2.63% from other businesses [1] Group 2 - As of the latest report, Hengtong's market capitalization stands at 10 billion yuan [2]